Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance in Age

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-26

Study Completion Date

2026-09-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of subjects \> 60 years of age respecting a male/female ratio = 1.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment

NCT06851975

Cancer

RECRUITING NA

Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy

NCT02133222

Metastatic (Stage IV) Melanoma

COMPLETED NA

Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.

NCT01079429

Monoclonal Gammopathy of Undetermined Significance Smoldering Myeloma

TERMINATED

Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues (SkinAge).

NCT02553954

Sarcoma

COMPLETED NA

Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib?

NCT05781425

Chemotherapy-induced Peripheral Neuropathy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of subjects \> 60 years of age respecting a male/female ratio = 1. After explanations and collection consent, collection of the patient's socio-demographic and medical characteristics and then carrying out a Peripheral venous blood sample (2 x 5ml tubes).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

evaluation of LAMP-2 protein expression

dosing of level expression of LAMP-2

Group Type OTHER

dosage

Intervention Type DIAGNOSTIC_TEST

Presence of mutation on the gene panel and Frequency of allele variation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dosage

Presence of mutation on the gene panel and Frequency of allele variation

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women over 60 years of age.

Exclusion Criteria

* Inability to Understand Consent,
* Non-Security Beneficiaries
* social, subjects protected by law, subjects deprived of liberty,
* history of breast cancer,
* brain tumor,
* melanoma,
* colon cancer,
* lung cancer,
* prostate cancer,
* lymphoma,
* myeloma,
* syndrome myelodysplastic/myeloproliferative,
* leukemia,
* history of radiation therapy.

Minimum Eligible Age

60 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No